2023-03-29 15:46:29 ET
- Shares of Alzheimer's drug developer Annovis Bio ( NYSE: ANVS ) rose ~17% Wednesday to the highest level since November 2021 as the company was scheduled to make a presentation disclosing late-stage data for its lead candidate buntanetap.
- Previously, Annovis ( ANVS ) announced the company was selected to conduct two presentations at an ongoing medical conference on Alzheimer's and Parkinson's Disease on Mar. 30 and Mar. 31 in Gothenburg, Sweden.
- The first presentation conducted by Dr. Cheng Fang focused on designs of the company's current Phase 2/3 study in Alzheimer's disease and the Phase 3 study in Parkinson's disease.
- It also included an interim analysis from the Phase 3 study for Parkinson's disease representing 30% of patients who have received two months of buntanetap.
- Issuing an enrollment update on the study, ( ANVS ) said in January the company expected interim data from the trial in Q2 2023.
For further details see:
Annovis Bio jumps 17% on the day of data presentation on lead asset